Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) PerformanceObligation Component	Dec. 31, 2015 USD ($)	Jul. 31, 2015 USD ($) PerformanceObligation
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		$ 705,138	$ 787,647	$ 587,367
AstraZeneca [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		129,759	202,236	$ 79,160
Deferred contract revenue	$ 0	$ 0	$ 0
AstraZeneca [Member] | Revenue [Member] | Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage		18.00%	26.00%	13.00%
WAINUA [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable over term of collaboration	3,600,000	$ 3,600,000
Upfront payment received					$ 200,000
Maximum amount of development milestone payments over term of collaboration	485,000	485,000
Maximum amount of sales milestone payments over term of collaboration	2,900,000	$ 2,900,000
Royalty percentage received on sales of medicine in U.S.		20.00%
Number of material components | Component					4
Number of separate performance obligations | PerformanceObligation					1
Transaction price					$ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca		55.00%
Revenue			$ 20,000
WAINUA [Member] | Maximum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Next payment to be achieved	200,000	$ 200,000
WAINUA [Member] | Minimum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Cumulative payments received	465,000	465,000
Next payment to be achieved	115,000	115,000
WAINUA [Member] | ATTRv-PN [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue	30,000
Cardiovascular, Renal and Metabolic Diseases [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable over term of collaboration	4,300,000	4,300,000
Upfront payment received						$ 65,000
Maximum amount of license fees over term of collaboration	175,000	175,000
Maximum amount of development milestone payments over term of collaboration	514,000	514,000
Maximum amount of regulatory milestone payments over term of collaboration	863,000	863,000
Maximum amount of sales milestone payments over term of collaboration	2,800,000	2,800,000
Next payment to be achieved	30,000	30,000
Number of separate performance obligations | PerformanceObligation							1
Transaction price							$ 65,000
Cumulative payments included in transaction price for performance obligation	90,000	$ 90,000
Revenue	25,000
Cardiovascular, Renal and Metabolic Diseases [Member] | Maximum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Royalty percentage received on net sales of medicine		10.00%
Cardiovascular, Renal and Metabolic Diseases [Member] | Minimum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Cumulative payments received	$ 340,000	$ 340,000